Journal of Neurology

, Volume 256, Issue 5, pp 796–802 | Cite as

Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy

  • Suvi Liimatainen
  • Mahdi Fallah
  • Elham Kharazmi
  • Maria Peltola
  • Jukka Peltola
Original Communication

Abstract

Previous studies have reported activation of inflammatory cytokines in seizures, but clinical characteristics of epilepsy associated with cytokine activation have not been well established. In this study, serum levels of interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1RA) were measured, and clinical characteristics of epilepsy were assessed in 86 well-evaluated patients with refractory focal epilepsy and in 5 patients with controlled focal epilepsy. Epilepsy was evaluated based on patient histories, electroclinical findings, and high-resolution brain MRI scans. Sixty-three healthy blood donors served as controls. IL-6 concentrations were chronically increased in epilepsy patients (11%) compared with healthy controls (0%) (P = 0.007). Increased levels of IL-6 were more prevalent in patients with temporal lobe epilepsy (TLE) compared to patients with extra-TLE (P = 0.028). Also the mean and the median serum levels of IL-6 were higher in patients with TLE than in patients with extra-TLE (P = 0.042). Concentrations of IL-1RA were not significantly different in patients compared with controls. Indicated by increased levels of IL-6 in TLE, epilepsy type is important in determining chronic overproduction of cytokines in refractory focal epilepsy. The results may reflect a chronic immunological process in the brain in patients with refractory epilepsy.

Keywords

Refractory focal epilepsy Cytokines Epilepsy type 

References

  1. 1.
    Penkowa M, Molinero A, Carrasco J, Hidalgo J (2001) Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures. Neuroscience 102:805–818CrossRefPubMedGoogle Scholar
  2. 2.
    Kalueff AV, Lehtimaki KA, Ylinen A, Honkaniemi J, Peltola J (2004) Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats. Neurosci Lett 22:106–110CrossRefGoogle Scholar
  3. 3.
    De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, De Luigi A, Garattini S, Vezzani A (2000) Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosc 12:2623–2633CrossRefGoogle Scholar
  4. 4.
    Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni MG, Sperk G, Andell-Jonsson S, Lundkvist J, Iverfeldt K, Bartfai T (2000) Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 10:11534–11539CrossRefGoogle Scholar
  5. 5.
    Allan S, Rothwell N (2007) Cytokines and acute neurodegeneration. Nat Rev Neurosci 2:734–744CrossRefGoogle Scholar
  6. 6.
    Vezzani A, Moneta D, Richichi C (2002) Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. Epilepsia 43:30–35CrossRefPubMedGoogle Scholar
  7. 7.
    Vezzani A, Granata T (2005) Brain inflammation of epilepsy: experimental and clinical evidence. Epilepsia 46:1724–1743CrossRefPubMedGoogle Scholar
  8. 8.
    Peltola J, Hurme M, Miettinen A, Keränen T (1998) Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 31:129–133CrossRefPubMedGoogle Scholar
  9. 9.
    Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, Lindholm D, Keränen T (2000) Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 41:205–211CrossRefPubMedGoogle Scholar
  10. 10.
    Woiciechowsky C, Schöning B, Daberkow N, Asche K, Stoltenburg G, Lanksch WR, Volk HD (1999) Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic–pituitary-adrenal axis and sympathetic nervous system. Brain Res 23:563–571CrossRefGoogle Scholar
  11. 11.
    Esch T, Stefano G (2002) Proinflammation: a common denominator or initiator of different pathophysiological disease processes. Med Sci Monit 8:HY1-9PubMedGoogle Scholar
  12. 12.
    Hulkkonen J, Koskikallio E, Rainesalo S, Keränen T, Peltola J (2004) The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res 59:199–205CrossRefPubMedGoogle Scholar
  13. 13.
    Sheng JG, Boop FA, Mrak RE, Griffin WS (1994) Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 63:1872–1879PubMedCrossRefGoogle Scholar
  14. 14.
    Crespel A, Coubes P, Rousset MC, Brana C, Rougier A, Rondouin G, Bockaert J, Baldy-Moulinier M, Lerner-Natoli M (2002) Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res 18:159–169CrossRefGoogle Scholar
  15. 15.
    Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A (2008) Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 29:142–160CrossRefPubMedGoogle Scholar
  16. 16.
    Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Vezzani A, Aronica E (2006) The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 24:128–143CrossRefPubMedGoogle Scholar
  17. 17.
    Peltola J, Kulmala P, Isojärvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keränen T, Graus F (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 12:46–50Google Scholar
  18. 18.
    Peltola JT, Haapala A, Isojärvi JI, Auvinen A, Palmio J, Latvala K, Kulmala P, Laine S, Vaarala O, Keränen T (2000) Antiphosholipid and antinuclear antibodies in epileptic syndromes and newly onset seizure disorders. Am J Med 109:712–717CrossRefPubMedGoogle Scholar
  19. 19.
    Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127:701–712CrossRefPubMedGoogle Scholar
  20. 20.
    Lehtimäki K, Keränen T, Huhtala H, Hurme M, Ollikainen J, Honkaniemi J, Palmio J, Peltola J (2004) Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. J Neuroimmunol 152:121–125CrossRefPubMedGoogle Scholar
  21. 21.
    Lehtimäki KA, Keränen T, Palmio J, Mäkinen R, Hurme M, Honkaniemi J, Peltola J (2007) Increased plasma levels of cytokines after seizures in localization-related epilepsy. Acta Neurol Scand 116:226–230CrossRefPubMedGoogle Scholar
  22. 22.
    Kwan P, Brodie MJ (2002) Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 11:77–84CrossRefPubMedGoogle Scholar
  23. 23.
    Mohanraj R, Brodie MJ (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neur 13:277–282CrossRefGoogle Scholar
  24. 24.
    Commission on Classification, Terminology of the International League Against Epilepsy (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389–399CrossRefGoogle Scholar
  25. 25.
    Commission on Neuroimaging of the International League Against Epilepsy (1997) Recommendations for neuroimaging of patients with epilepsy. Epilepsia 38:1255–1256CrossRefGoogle Scholar
  26. 26.
    Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M (2000) Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann Neurol 47:571–574CrossRefPubMedGoogle Scholar
  27. 27.
    Peltola J, Keränen T, Rainesalo S, Hurme M (2001) Polymorphism of the interleukin-1 gene complex in localization-related epilepsy. Ann Neurol 50:275–276CrossRefPubMedGoogle Scholar
  28. 28.
    Buono RJ, Ferraro TN, O′Connor MJ, Sperling MR, Ryan SG, Scattergood T, Mulholland N, Gilmore J, Lohoff FW, Berrettini WH (2001) Lack of association between an interleukin 1 beta (IL-1beta) gene variation and refractory temporal lobe epilepsy. Epilepsia 42:782–784CrossRefPubMedGoogle Scholar
  29. 29.
    Lim C, Alexander MP, LaFleche G, Schnyer DM, Verfaellie M (2004) The neurological and cognitive sequelae of cardiac arrest. Neurology 23:1774–1778Google Scholar
  30. 30.
    Freund TF, Ylinen A, Miettinen R, Pitkänen A, Lahtinen H, Baimbridge KG, Riekkinen PJ (1992) Pattern of neuronal death in the rat hippocampus after status epilepticus. Relationship to calcium binding protein content and ischemic vulnerability. Brain Res Bull 28:27–38CrossRefPubMedGoogle Scholar
  31. 31.
    Getts DR, Balcar VJ, Matsumoto I, Müller M, King NJ (2008) Viruses and the immune system: their roles in seizure cascade development. J Neurochem 104:1167–1176CrossRefPubMedGoogle Scholar
  32. 32.
    Bien CG, Urbach H, Schramm J, Soeder BM, Becker AJ, Voltz R, Vincent A, Elger CE (2007) Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 18:1236–1244CrossRefGoogle Scholar
  33. 33.
    Pitkänen A, Sutula TP (2002) Is epilepsy a progressive disorder? prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 1:173–181CrossRefPubMedGoogle Scholar
  34. 34.
    Majak K, Pitkänen A (2003) Projections from the periamygdaloid cortex to the amygdaloid complex, the hippocampal formation, and the parahippocampal region: a PHA-L study in the rat. Hippocampus 13:922–942CrossRefPubMedGoogle Scholar
  35. 35.
    Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, Larson MG, Meigs JB, Keaney JF Jr, Lipinska I, Kathiresan S, Benjamin EJ, DeCarli C (2007) Inflammatory biomarkers are associated with total brain volume: the Framingham heart study. Neurology 27:1032–1038CrossRefGoogle Scholar
  36. 36.
    Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM (2004) Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 61:668–672CrossRefPubMedGoogle Scholar
  37. 37.
    McGeer PL, Rogers J, McGeer EG (2006) Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimer′s Dis 9:271–276Google Scholar
  38. 38.
    Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 90:10061–10065CrossRefPubMedGoogle Scholar
  39. 39.
    Panegyres PK, Hughes J (1998) The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene. J Neurol Sci 5:123–132CrossRefGoogle Scholar
  40. 40.
    Xiao E, Xia L, Ferin M, Wardlaw SL (1999) Intracerebroventricular injection of interleukin-1 stimulates the release of high levels of interleukin-6 and interleukin-1 receptor antagonist into peripheral blood in the primate. J Neuroimmunol 97:70–76CrossRefPubMedGoogle Scholar
  41. 41.
    Meierkord H, Shorvon S, Lightman S, Trimble M (1992) Comparison of the effects of frontal and temporal lobe partial seizures on prolactin levels. Arch Neurol 49:225–230PubMedGoogle Scholar
  42. 42.
    Miyawaki T, Sogawa N, Maeda S, Kohjitani A, Shimada M (2001) Effect of midazolam on interleukin-6 mRNA expression in human peripheral blood mononuclear cells in the absence of lipopolysaccharide. Cytokine 15:320–327CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Suvi Liimatainen
    • 1
  • Mahdi Fallah
    • 2
  • Elham Kharazmi
    • 2
  • Maria Peltola
    • 1
  • Jukka Peltola
    • 1
  1. 1.Department of Neurology and RehabilitationTampere University HospitalTampereFinland
  2. 2.Tampere School of Public HealthUniversity of TampereTampereFinland

Personalised recommendations